R. Ofri et al., The effect of 0.12% unoprostone isopropyl (Rescula) on intraocular pressure in normotensive dogs, J VET MED S, 62(12), 2000, pp. 1313-1315
Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound appr
oved for treatment of glaucoma in humans. It is commercially available in J
apan, and is undergoing clinical testing elsewhere. The aim of this study w
as to evaluate the effect of Rescula on intraocular pressure (IOP) in normo
tensive dogs. After establishing a baseline diurnal IOP curve, six dogs wer
e unilaterally treated with Rescula while the contralateral eye was treated
with a placebo. Applanation tonometry was performed in both eyes, and pupi
l size was evaluated, 30 min after treatment, and at 1-hr intervals for the
next 9 hr. Rescula caused a significant (p=0.014) and longlasting decrease
in IOP, from 20.49 +/- 2.02 mm Hg in control eyes to 15.49 +/- 0.69 mm Hg
in treated eyes. These results suggest that Rescula is potentially efficaci
ous in treatment of canine glaucoma.